NOTIFICATION LETTER 通知信函 Dear Registered Shareholders. EuroEyes International Eye Clinic Limited (the "Company") – Notice of publication of 2025 Interim Report ("Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at ir.euroeyes.hk and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends ...

Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 377,125,000, representing a 2.4% increase from HKD 368,372,000 in 2024[8] - Gross profit for the same period was HKD 156,816,000, up 5.9% from HKD 148,013,000 in 2024[8] - Adjusted net profit after tax decreased by 37.7% to HKD 38,817,000 from HKD 62,285,000 in 2024[8] - The company reported a net profit of HKD 40,405,000, down 12.7% from HKD 46,309,000 in the previous year[8] - Adjusted gross profit was HKD 156,816,000, slightly down by 0.8% from HKD 158,146,000 in 2024[8] - Operating profit increased to HKD 72,554,000, representing an increase of 10.0% from HKD 65,741,000 in 2024[23] - Profit before tax decreased to HKD 57,797,000, down 18.0% from HKD 70,444,000 in the previous year[23] - Total comprehensive income for the period was HKD 202,230,000, significantly higher than HKD 32,341,000 in the same period last year[24] - Basic earnings per share for the period was HKD 11.999, a decrease from HKD 13.311 in 2024[24] - EBITDA for the same period is HKD 131,821,000, leading to a profit before tax of HKD 57,797,000[59] Assets and Liabilities - Total assets as of June 30, 2025, amounted to HKD 1,811,810, an increase of 13.2% from HKD 1,599,435 as of December 31, 2024[17] - Non-current assets increased to HKD 996,664, up 12.5% from HKD 885,835 at the end of 2024[17] - Total liabilities as of June 30, 2025, were HKD 512,513, an increase of 8.2% from HKD 473,721 at the end of 2024[21] - The company’s equity attributable to owners increased to HKD 1,264,762, up 15.7% from HKD 1,092,965 at the end of 2024[17] - Cash and cash equivalents reached HKD 741,782, representing a 13.5% increase from HKD 653,232 at the end of 2024[17] - Trade receivables increased significantly to HKD 14,171, up from HKD 4,738 at the end of 2024, indicating a growth of 198.5%[17] Foreign Exchange and Financial Management - The financial results reflect the impact of pre-opening expenses for new clinics and foreign exchange losses related to global offerings[9] - The company reported a foreign exchange loss related to global offering proceeds of HKD 513, compared to HKD 323 in 2024[11] - The company experienced a foreign exchange loss due to the appreciation of the Euro against the RMB and HKD by 11.7% and 13.4%, respectively[112] - The group maintains a prudent liquidity risk management policy, ensuring sufficient cash and credit facilities[42] - The expected credit loss rate for cash and cash equivalents is assessed as not significant, with no provisions made as of June 30, 2025[41] Strategic Outlook and Growth Plans - The management plans to continue focusing on market expansion and new clinic openings to drive future growth[10] - The company is committed to enhancing its service offerings through the development of new technologies and products[10] - Future guidance indicates a cautious outlook due to the current economic environment and its impact on consumer spending[10] - The company anticipates a compound annual growth rate (CAGR) of 10% for revenue and 20% for net profit by 2028, supported by a diversified global business portfolio[120] - The company plans to actively seek suitable acquisition opportunities to significantly enhance organic growth over the next two to three years[120] Employee and Operational Expenses - Employee benefits expenses decreased slightly to HKD 122,204,000 in 2025 from HKD 123,470,000 in 2024, a reduction of 1.0%[72] - Selling expenses increased by 14.9% to HKD 41.8 million, representing 11.1% of total revenue, up from 9.9% in 2024[132] - Administrative expenses were HKD 48.8 million, consistent with the previous year, accounting for 12.9% of total revenue, down from 13.2%[134] Shareholder Information - The company proposed an interim dividend of HKD 0.0315 per share for the six months ended June 30, 2025, totaling HKD 10,102,239, compared to HKD 11,570,153 in 2024[83] - The company has not issued any further share-based payments since 2025, indicating a potential shift in compensation strategy[94] - The total issued shares as of June 30, 2025, were 320,706,000[156] - Dr. Jørn Slot Jørgensen holds a controlling interest of 57.65% in the company[152] Governance and Compliance - The company has maintained compliance with the corporate governance code as per the listing rules, with a review of governance procedures conducted[168] - The board believes that the current governance structure does not undermine the balance of power and authority within the company[169] - The audit committee reviewed the unaudited condensed consolidated results for the six months ended June 30, 2025, and had no objections to the accounting treatments adopted[178]

Group 1 - The acquisition allows EuroEyes to establish a presence in major Swiss cities and strengthen its position in the London market [1] - The board views this acquisition as a strategic expansion into the Swiss market and a consolidation of its position in the UK market, which is expected to contribute positively to the group's long-term growth [1] Group 2 - EuroEyes Swiss will acquire seven refractive surgery clinics, one refractive surgery treatment operating room, and related headquarters assets from Betterview Swiss for 12.01 million Swiss francs (approximately 117 million Hong Kong dollars) [3] - EuroEyes UK will acquire related assets of Betterview UK's ophthalmic services for 200,000 Swiss francs (approximately 1.94886 million Hong Kong dollars) [3]

Group 1 - The company announced the acquisition of Swiss and UK assets from Betterview, with a total consideration of approximately 12.01 million Swiss francs (about 1.17 billion HKD) for Swiss assets and 200,000 Swiss francs (approximately 18,442 GBP and 1.94886 million HKD) for UK assets [1][2] - The Swiss assets include seven refractive surgery clinics located in major cities such as Zurich, Bern, and Geneva, along with a surgical room and various headquarters assets, including contracts, customer data, and medical equipment [2][3] - The acquisition is expected to strategically expand the company's presence in the important European market of Switzerland and strengthen its position in the UK, contributing positively to long-term growth [3] Group 2 - The company primarily engages in refractive surgery services, and the acquired clinics have generated recurring revenue and possess a solid customer base [3] - The board believes that the terms of the acquisition are fair and reasonable, aligning with the overall interests of the company and its shareholders [3]

Group 1 - EuroEyes Swiss, a wholly-owned subsidiary of the company, has entered into an agreement to acquire Swiss assets from Betterview Swiss for a total consideration of 12.01 million Swiss Francs (approximately 117 million HKD) [1] - The assets to be acquired include seven refractive surgery medical clinics located in Zurich, Bern, Lucerne, St. Gallen, Lugano, Lausanne, and Geneva, as well as a refractive surgery operating room in Zurich [1] - The acquisition also includes various headquarters assets such as commercial contracts, customer contracts, employment contracts, leasing contracts, and past patient agreements (excluding those retained by Betterview Swiss) [1] Group 2 - EuroEyes UK, another wholly-owned subsidiary of the company, has signed an agreement to acquire UK assets from Betterview UK for a total consideration of 200,000 Swiss Francs (approximately 184,400 GBP and 1.949 million HKD) [2] - The assets to be acquired consist of properties, assets, and rights used in Betterview UK's ophthalmic services business, which operates under the names "Betterview" or "Betterview Britain" [2] - The UK business includes services such as laser treatment and refractive surgery, but excludes certain business debts, cash on hand or in banks, and any recoverable tax amounts related to the UK business [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 EuroEyes International Eye Clinic Limited 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） 須予披露的交易 透過附屬公司收購瑞士及英國資產 收購事項 董事會欣然宣佈，於2025年9月2日（交易時段後），EuroEyes Swiss（作為買 方）、本公司（作為擔保人）與Betterview Swiss（作為賣方）訂立瑞士協議，據此 EuroEyes Swiss同意購買，及Betterview Swiss同意出售瑞士資產，瑞士代價總 額為12,010,000瑞士法郎（相當於約117,029,043港元）。 董事會亦欣然宣佈，於2025年9月2日（交易時段後），EuroEyes UK（作為買方） 與Betterview UK（作為賣方）訂立英國協議，據此EuroEyes UK同意購買，及 Betterview UK同意出售英國資產，英國代 ...

公司名稱: 德視佳國際眼科有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01846 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | 本月底法定/註冊股本總額： USD 10,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證 ...

Core Viewpoint - 德视佳 (01846) reported a revenue of HKD 377 million for the six months ending June 30, 2025, representing a year-on-year increase of 2.4% [1] - The company's profit for the same period was HKD 40.405 million, reflecting a year-on-year decrease of 12.7% [1] - Basic earnings per share stood at HKD 0.11999 [1] Financial Performance - Revenue for the period reached HKD 377 million, up 2.4% compared to the previous year [1] - Profit decreased to HKD 40.405 million, down 12.7% year-on-year [1] - Basic earnings per share were reported at HKD 0.11999 [1]

Group 1 - The company, 德视佳 (01846), reported a revenue of HKD 377 million for the six months ending June 30, 2025, representing a year-on-year increase of 2.4% [1] - The company's profit for the same period was HKD 40.405 million, which reflects a year-on-year decrease of 12.7% [1] - The basic earnings per share for the company were HKD 0.11999 [1]

EF001 EF001 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括執行董事Jørn Slot Jørgensen醫生、Markus Braun博士、Jannik Jonas Slot Jørgensen先生 及 Dan Zoltan Reinstein 教授；非執行董事Marcus Huascar Bracklo先生；及獨立非執行董事Hans Helmuth Hennig先生、Katherine 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | | 股票發行人現金股息公告 | | 發行人名稱 | 德視佳國際眼科有限公司 | | 股份代號 | 01846 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年8月28日 | | 公告狀態 | 新公告 | | 股 ...